IFF's big portfolio overhaul and buyback drive the story
IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.
This is the biggest strategic event of the period, reshaping IFF's business and capital returns.
Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.
The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.
New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.
Product launches show IFF's innovation pipeline and support future revenue growth.
Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.
This reflects external validation of IFF's turnaround story and potential upside.